Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease

Edward L. Hannan, Chuntao Wu, Gary Walford, Alfred T. Culliford, Jeffrey P. Gold, Craig R. Smith, Robert S.D. Higgins, Russell E. Carlson, Robert H. Jones

Research output: Contribution to journalArticle

446 Scopus citations

Abstract

BACKGROUND: Numerous studies have compared the outcomes of two competing interventions for multivessel coronary artery disease: coronary-artery bypass grafting (CABG) and coronary stenting. However, little information has become available since the introduction of drug-eluting stents. METHODS: We identified patients with multivessel disease who received drug-eluting stents or underwent CABG in New York State between October 1, 2003, and December 31, 2004, and we compared adverse outcomes (death, death or myocardial infarction, or repeat revascularization) through December 31, 2005, after adjustment for differences in baseline risk factors among the patients. RESULTS: In comparison with treatment with a drug-eluting stent, CABG was associated with lower 18-month rates of death and of death or myocardial infarction both for patients with three-vessel disease and for patients with two-vessel disease. Among patients with three-vessel disease who underwent CABG, as compared with those who received a stent, the adjusted hazard ratio for death was 0.80 (95% confidence interval [CI], 0.65 to 0.97) and the adjusted survival rate was 94.0% versus 92.7% (P=0.03); the adjusted hazard ratio for death or myocardial infarction was 0.75 (95% CI, 0.63 to 0.89) and the adjusted rate of survival free from myocardial infarction was 92.1% versus 89.7% (P<0.001). Among patients with two-vessel disease who underwent CABG, as compared with those who received a stent, the adjusted hazard ratio for death was 0.71 (95% CI, 0.57 to 0.89) and the adjusted survival rate was 96.0% versus 94.6% (P=0.003); the adjusted hazard ratio for death or myocardial infarction was 0.71 (95% CI, 0.59 to 0.87) and the adjusted rate of survival free from myocardial infarction was 94.5% versus 92.5% (P<0.001). Patients undergoing CABG also had lower rates of repeat revascularization. CONCLUSIONS: For patients with multivessel disease, CABG continues to be associated with lower mortality rates than does treatment with drug-eluting stents and is also associated with lower rates of death or myocardial infarction and repeat revascularization.

Original languageEnglish (US)
Pages (from-to)331-341
Number of pages11
JournalNew England Journal of Medicine
Volume358
Issue number4
DOIs
StatePublished - Jan 24 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease'. Together they form a unique fingerprint.

  • Cite this

    Hannan, E. L., Wu, C., Walford, G., Culliford, A. T., Gold, J. P., Smith, C. R., Higgins, R. S. D., Carlson, R. E., & Jones, R. H. (2008). Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. New England Journal of Medicine, 358(4), 331-341. https://doi.org/10.1056/NEJMoa071804